According to Pearl Therapeutics, it has completed two Phase 2b clinical studies of PT003, its inhaled combination bronchodilator for the treatment of moderate-to-severe COPD, and is "on-track to commence Phase 3 program in 2012." One of the trials was a dose confirmation study of various doses of PT003 compared to its components, PT001 and PT005; the other was a … [Read more...] about Pearl ready to begin Phase 3 studies of PT003
News
Lustren Consulting now offering inhalation device development services
Launched officially on January 1, 2012, Lustren Consulting is now offering "specialist management consultancy for device development in the healthcare industry" with particular expertise in inhalation device development. The company, which was unofficially introduced at DDL 22. says that it is "focused on helping clients achieve their device related business goals and … [Read more...] about Lustren Consulting now offering inhalation device development services
Positive Phase 1 results for inhaled L-dopa
Civitas Therapeutics has announced positive results from a Phase 1 clinical study of its CVT-301 inhaled dry powder formulation of levodopa (L-dopa) for the treatment of Parkinson’s disease. According to the company, the study showed that all of the doses tested were well tolerated, and sufficient plasma levels of L-dopa were achieved in healthy volunteers who inhaled … [Read more...] about Positive Phase 1 results for inhaled L-dopa
Phase 2 study of ISTA’s bepotastine-steroid nasal spray begins
ISTA Pharmaceuticals says that it has initiated a Phase 2 study of its Beposone bepotastine besilate/steroid combination nasal spray for the treatment of seasonal allergic rhinitis. Approximately 600 patients with allergic rhinitis caused by mountain cedar pollen are expected to take part in the randomized, placebo-controlled, parallel-group environmental study, which … [Read more...] about Phase 2 study of ISTA’s bepotastine-steroid nasal spray begins
Pulmatrix gets patent for inhalation formulations
The European Patent Office has granted patent number EP 2315580 B1 to Massachusetts biotech company Pulmatrix for "Pharmaceutical formulations and methods for treating respiratory tract infections.” The patent covers "both dry powder and liquid formulations with optimized ranges of the formulation components, and also describes methods for treating respiratory … [Read more...] about Pulmatrix gets patent for inhalation formulations
Elevation gets funding for development of nebulized glycoprrolate
California-based Elevation Pharmaceuticals has announced closing of $30 million in Series B financing for development of its lead product, EP-101, a glycopyrrolate inhalation solution for the treatment of COPD. Novo Ventures, a new investor, led the round, and Elevation's previous investors, Canaan Partners, TPG Biotech, Care Capital, and Mesa Verde Venture Partners, … [Read more...] about Elevation gets funding for development of nebulized glycoprrolate
Happy New Year from OINDPnews
VaryDose appoints Philippe Rogueda as CTO
UK dry powder dispensing company VaryDose has announced the appointment of Philippe Rogueda as its Chief Technology Officer. According to the company, "Philippe brings with him many years’ experience and expertise in the powder handling and pharmaceutical formulation industry. Philippe is an industry renowned product development specialist with extensive experience of … [Read more...] about VaryDose appoints Philippe Rogueda as CTO
Pharmaxis files resubmission for Bronchitol to PBAC
Pharmaxis has announced that it "filed a minor resubmission with the Pharmaceutical Benefits Advisory Committee (PBAC)" for its Bronchitol mannitol dry powder inhaler for the treatment of cystic fibrosis. According to the company, the committee's next scheduled meeting is in March 2012, at which time it will consider the submission. Bronchitol received marketing … [Read more...] about Pharmaxis files resubmission for Bronchitol to PBAC
Pulmatrix says iSperse data show superiority over lactose blends for DPIs
Pulmatrix has presented data at the 11th US-Japan Symposium on Drug Delivery Systems in Hawaii that it says demonstrate the superiority of its iSPERSE inhalation platform over lactose formulations for combination dry powder inhalers. The iSPERSE technology makes use of a "delivery matrix containing proprietary cationic salt formulations" that allows for increased … [Read more...] about Pulmatrix says iSperse data show superiority over lactose blends for DPIs